AbbVie

AbbVie makes inroads in orphan drugs

AbbVie makes inroads in orphan drugs

By

Not long after acquiring Shire to add to its orphan-drug portfolio, the drugmaker scored an orphan designation from both FDA and EMA last week.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

By

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.

AbbVie art gallery: a glimpse into patient POV

AbbVie art gallery: a glimpse into patient POV

By

AbbVie's "Perspectives—Art, Inflammation and Me," an exhibit centered around inflammatory diseases, looks to offer patient perspective through an artistic medium.

AbbVie's all-oral HCV combo shines in trial

AbbVie's all-oral HCV combo shines in trial

By

Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?

Email Newsletters